Related Experiment Videos
Cost-benefit analysis of BCG-vaccination in Austria
Insights
The cost-benefit analysis of Bacillus Calmette-Guérin (BCG) vaccination in Austria indicates that vaccinating newborns is cost-neutral. However, vaccinating schoolchildren offers significant economic advantages and improves overall vaccination effectiveness.
Area of Science:
- Public Health
- Epidemiology
- Health Economics
Background:
- Bacillus Calmette-Guérin (BCG) vaccination is standard for newborns in Austria, with limited application in school children.
- Tuberculosis (TB) remains a public health concern, necessitating evaluation of vaccination strategies.
Purpose of the Study:
- To conduct a cost-benefit analysis of age-dependent BCG vaccination strategies in Austria.
- To evaluate the economic impact of BCG vaccination in newborns versus school children.
Main Methods:
- A cost-benefit analysis was performed.
- Factors considered included age-specific immunization, TB morbidity, vaccine efficacy and duration, vaccination costs, TB treatment costs, and complication management costs.
Main Results:
- BCG vaccination of newborns demonstrates an economic balance, where vaccination costs are offset by savings from prevented TB cases.
- Vaccination of school children yields a substantial economic gain.
- General revaccination of schoolchildren significantly enhances the economic efficiency of BCG vaccination.
Conclusions:
- BCG vaccination in newborns is economically neutral.
- Targeted BCG vaccination of schoolchildren presents a considerable economic benefit.
- Expanding BCG revaccination programs for schoolchildren can increase the overall economic effectiveness of the vaccination strategy.
Abstract:
BCG-vaccination in Austria is performed generally in newborn, but only partially in school children. A cost-benefit analysis was performed considering age-dependent immunizations, tuberculosis morbidity, protection rate and duration of protection, costs of vaccination, costs of tuberculosis therapy, frequency of complications due to vaccination and costs for treatment of these complications. This analysis shows an economic balance between costs and benefits with regard to immunication of newborn, i. e., costs of vaccination are approximately compensated by the saved costs of prevented diseases. In contrary vaccination of school children reveals a considerable economic gain. General revaccination of schoolchildren would make BCG-vaccination much more effective in an economic respect.